Maxime Dely: Blood Plasma Remains the Only Possible Source of Human Albumin
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Plasma: an irreplaceable source of albumin
The bag in this photo? That’s my plasma. A small gesture that hides a much bigger reality…
Did you know that blood plasma is today the only possiblesource for producing human albumin?
This protein, which represents approximately 4 % of plasma, plays a fundamental role in therapeutic plasma exchange — a technique used to treat severe autoimmune diseases, neurological conditions, and acute liver failure.
In France, a single plasma donation is limited to 855 ml maximum. That may seem like a small amount… but each bag contains approximately 30-40 g of albumin, precious and irreplaceable.
No chemical synthesis, no technology can reproduce this molecule. Only the human body produces it. Only donation makes it possible to collect it.
Plasma means giving far more than a biological fluid. It means enabling patients in critical condition to receive a life-saving treatment.
Think about it.”
Stay updated with Hemostasis Today.
-
Mar 8, 2026, 07:28Arun V J: Is Plasma The Semiconductor Chips In Healthcare?
-
Mar 8, 2026, 07:26Roberta Gualtierotti: Can Artificial Intelligence Help Detect Early Joint Bleeding in Hemophilia?
-
Mar 8, 2026, 07:23Marty Pack: Increased Mortality and Complications in Stroke Patients with COVID-19
-
Mar 8, 2026, 07:17Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy
-
Mar 7, 2026, 16:24Kalpana Gupta Shekhawat: The Overlooked Regulator of Mast Cells – Understanding the Vagus Nerve
-
Mar 7, 2026, 16:20Purusotham Chippala: How DALYs Reveal the True Burden of Stroke
-
Mar 7, 2026, 16:13Ilenia Calcaterra: Patient-Level Real-World Outcomes of Emicizumab in Acquired Hemophilia A
-
Mar 7, 2026, 16:05Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
-
Mar 7, 2026, 15:58Aurelio Maggio: The Mission and The Projects We Are Advancing for Rare Hematologic Diseases